ACS Fall 2025 First-Time Disclosures: One Year On
With ACS Fall 2026 heading to Chicago from August 23–27, the popular First-Time Disclosures session returns on August 26. To whet the appetite, we're looking back at the 13 clinical-stage candidates and discovery programmes unveiled at ACS Fall 2025 in Washington, DC—and where they stand one year later. BMS-986463 \(BMS\) – A molecular glue degrader of WEE1 for solid tumours, including NSCLC, ovarian and uterine cancers. Phase 1 dose escalation is ongoing. BMS-986470 \(BMS\) – A dual ZBTB7A/WIZ molecular glue designed to reactivate fetal haemoglobin in sickle cell disease. It represents a novel approach to HbF induction. Emvistegrast/GS-1427 \(Gilead\) – An oral α4β7 integrin inhibitor for ulcerative colitis. The Phase 2 SWIFT trial has completed its primary period, with the overall study continuing. PF-07899895 \(Pfizer\) – A colon-targeted pan-SIK inhibitor being investigated for inflammatory bowel disease. Public updates on clinical progress have been limited. AZD0233 \(AstraZeneca\) – A CX3CR1 antagonist investigated for dilated cardiomyopathy. Development was halted following a finding in a nonclinical chronic toxicology study. PF-07293893 \(Pfizer\) – An AMPKγ3 activator developed for heart failure with preserved ejection fraction. The programme has been discontinued. \[11C\]MK-7337 \(Merck\) – An α-synuclein PET imaging ligand for Parkinson's disease. Follow-on development has shifted towards the next-generation fluorine-18 tracer MK-0947, now being studied clinically. FOG-001 \(Parabilis Medicines\) – A first-in-class inhibitor of the β-catenin–TCF interaction. Phase 1/2 development continues following FDA Fast Track designation for desmoid tumours in November 2025. TYRA-200 \(Tyra Biosciences\) – A covalent FGFR2 inhibitor for advanced or metastatic intrahepatic cholangiocarcinoma and other FGFR2-driven solid tumors. Phase 1 SURF201 development continues. MOMA-341 \(MOMA Therapeutics\) – A covalent WRN helicase inhibitor targeting MSI-H/dMMR solid tumours. Phase 1 development is ongoing. ETN029 \(Mariana Oncology/Novartis\) – A DLL3-targeted alpha-emitting radioligand for solid tumours including SCLC. Its Phase 1 study began in October 2025 and is recruiting. LRK-4189 \(Larkspur Biosciences\) – A first-in-class PIP4K2C degrader being developed for MSS colorectal cancer. Clinical development is underway. IID432 \(Novartis\) – A reversible covalent T. cruzi topoisomerase II inhibitor for Chagas disease. The programme remains an interesting example of translational drug discovery in a neglected disease. 2026 has been an exciting year for small molecule drug discovery. We have seen Veppanu, the first FDA-approved PROTAC and Orforglipron, the first FDA-approved oral, non-peptide GLP-1 receptor agonist. If last year’s First-Time Disclosures is anything to go by, we will be watching 2026 closely. Which talk excites you most in the 2026 line up?